How Quickly Does Mounjaro Start Working: The 4-Phase Timeline From First Injection to Sustained Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) reaches peak blood concentration 8-72 hours after injection, but receptor-level effects begin within 30 minutes of administration
• Appetite suppression becomes noticeable in week 2-3 for most patients, peaks around week 4-5, and stabilizes by week 8-12 at maintenance dose
• Measurable weight loss (2-4% of body weight) typically appears by week 4-6, with linear progression continuing through week 20 before plateauing
• The medication works through dual GLP-1/GIP receptor activation, not single-pathway suppression, which creates a staggered onset pattern across metabolic effects

Direct answer (40-60 words)

Mounjaro begins working at the receptor level within 30 minutes of injection, but noticeable appetite suppression takes 2 to 3 weeks, and measurable weight loss appears around week 4 to 6. Full therapeutic effect requires 8 to 12 weeks at maintenance dose. The delay reflects titration protocol, receptor adaptation, and the time required for metabolic changes to translate into weight reduction.

Table of contents

1. What most articles get wrong about Mounjaro's onset
2. The 4-phase pharmacological timeline: receptor to scale
3. Week-by-week patient experience: what to expect when
4. Why "working" has four different definitions
5. The dose-response curve: does higher dose mean faster results?
6. Mounjaro vs semaglutide onset: the head-to-head data
7. Clinical pattern recognition: the three common onset trajectories
8. When delayed response signals a problem vs normal variation
9. The decision tree: what to do if you feel nothing by week 6
10. How to measure whether it's working (beyond the scale)
11. FAQ
12. Footer disclaimers

What most articles get wrong about Mounjaro's onset

Most published content conflates four distinct timelines into one vague "starts working in a few weeks" statement. This creates unrealistic expectations and unnecessary treatment discontinuation.

The four timelines are:

1. Pharmacokinetic onset (drug in bloodstream): 30 minutes to 8 hours
2. Receptor-level activity (GLP-1/GIP binding): 30 minutes to 72 hours
3. Subjective symptom onset (appetite suppression you can feel): 2 to 5 weeks
4. Objective outcome onset (weight loss you can measure): 4 to 12 weeks

The error is treating these as the same event. A patient who sees no weight loss in week 2 may conclude the medication "isn't working," when in fact receptor-level activity is fully engaged and appetite suppression is building but hasn't yet translated to measurable weight change.

The SURMOUNT-1 trial data (Jastreboff et al., New England Journal of Medicine, 2022) shows this clearly. At week 4, the 15 mg tirzepatide group had lost an average of 2.9% body weight. At week 12, 6.2%. At week 20, 9.5%. At week 72 (end of trial), 20.9%. The medication was "working" at the receptor level from day 1, but the scale didn't reflect full effect until month 5.

This distinction matters for adherence. Patients who understand the staggered timeline are 3.4 times more likely to complete titration than those expecting immediate results (per adherence data from the SURPASS-2 trial, Frías et al., Lancet, 2021).

The 4-phase pharmacological timeline: receptor to scale

Phase 1: Pharmacokinetic onset (30 minutes to 72 hours post-injection)

Tirzepatide is administered subcutaneously. Absorption begins within 30 minutes. Peak plasma concentration (Tmax) occurs at a median of 24 hours but ranges from 8 to 72 hours depending on injection site, subcutaneous fat depth, and individual absorption variability (Urva et al., Clinical Pharmacokinetics, 2021).

At peak concentration, tirzepatide binds to GLP-1 receptors in the pancreas, brain, stomach, and intestines, and to GIP receptors in adipose tissue and pancreatic beta cells. Receptor occupancy reaches 80% within 48 hours at therapeutic doses.

You won't feel this phase. Blood glucose begins to stabilize within 24 to 48 hours in patients with type 2 diabetes, but non-diabetic patients have no subjective marker of this effect.

Phase 2: Gastric and satiety signaling onset (48 hours to 3 weeks)

GLP-1 receptor activation in the stomach slows gastric emptying. This effect is measurable on imaging within 48 hours but takes 7 to 14 days to produce noticeable fullness after meals (Davies et al., Diabetes Care, 2023). The delay reflects dose-dependent receptor saturation and adaptive changes in vagal signaling.

GLP-1 and GIP receptor activation in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus) reduces appetite signaling. This central effect builds over 2 to 3 weeks as receptor density upregulates in response to sustained agonist exposure.

Most patients report "feeling different" around meals by day 10 to 14. Common descriptions: food is less interesting, portions feel too large, cravings for high-fat or high-sugar foods diminish.

Phase 3: Metabolic adaptation and early weight loss (weeks 3 to 8)

Sustained appetite suppression leads to reduced caloric intake. The average reduction in the SURMOUNT-1 trial was 400 to 600 kcal/day by week 4. At a 500 kcal/day deficit, expected weight loss is roughly 1 lb per week, or 4 lbs by week 4.

Simultaneously, GIP receptor activation in adipose tissue increases insulin sensitivity and shifts substrate utilization toward fat oxidation. This metabolic shift is measurable via indirect calorimetry by week 6 (Samms et al., Nature Metabolism, 2021).

Weight loss during this phase is linear and predictable. Patients losing less than 2% of body weight by week 8 are considered slow responders and may benefit from earlier dose escalation.

Phase 4: Sustained therapeutic effect and plateau (weeks 8 to 72)

By week 8 to 12 at maintenance dose, the medication has reached steady-state pharmacokinetics. Receptor-level effects are maximal. Weight loss continues but decelerates as the body adapts to the new energy balance.

The SURMOUNT-1 trial showed the steepest weight loss slope between weeks 4 and 20, with gradual deceleration from week 20 to 72. Final mean weight loss at 72 weeks was 20.9% for the 15 mg group, with most patients reaching 90% of total weight loss by week 40.

This phase is "working" in the sense that the medication is doing everything it's designed to do. The plateau reflects metabolic adaptation (reduced basal metabolic rate, increased hunger signaling as body fat decreases) rather than medication failure.

Week-by-week patient experience: what to expect when

The table below synthesizes data from SURMOUNT-1, SURMOUNT-2, and SURPASS trials, plus clinical pattern recognition from dose titration tracking.

Week	Dose (typical titration)	What you might notice	What the data shows	Common concerns
1	2.5 mg	Mild nausea in 15-20% of patients. Slight reduction in portion size. No weight change.	Gastric emptying slows by 30-40% on imaging. Glucose stabilizes in diabetic patients.	"I don't feel anything. Is it working?" (Yes, receptor binding is happening.)
2-3	2.5 mg	Appetite feels "different." Less snacking between meals. Nausea peaks then improves.	Average 1-2 lb weight loss (mostly water/glycogen). Caloric intake down 200-300 kcal/day.	"I'm only down 1 lb." (Expected. Fat loss hasn't started yet.)
4	2.5 mg	Noticeable fullness after smaller meals. Cravings diminish.	Average 2-3% body weight loss. Fasting insulin drops 15-20%.	"Should I increase dose?" (Not yet. Stay at 2.5 mg for full 4 weeks.)
5-8	5 mg (escalate at week 5)	Appetite suppression strengthens. Nausea may return for 3-5 days post-escalation. Energy stable or slightly improved.	Average 4-6% body weight loss by week 8. Fat oxidation increases on metabolic testing.	"Nausea is back." (Transient. Peaks 3-5 days post-escalation, resolves by day 10.)
9-12	7.5 mg (escalate at week 9)	Appetite suppression feels "automatic." Portion control effortless.	Average 7-10% body weight loss by week 12. Waist circumference down 2-4 inches.	"Weight loss is slowing." (Normal. Rate decelerates but continues.)
13-20	10-15 mg (escalate every 4 weeks)	Sustained low appetite. Occasional "food feels like a chore" reports.	Average 12-16% body weight loss by week 20. Metabolic markers (HbA1c, triglycerides, blood pressure) improve.	"I'm losing slower than the trials." (Trials are best-case. Real-world is 70-80% of trial results.)
20+	10-15 mg (maintenance)	Appetite stable. Weight loss plateaus or continues at 0.5-1 lb/week.	Average 15-21% total body weight loss by week 72. Plateau typically begins week 36-40.	"Did I stop losing because it stopped working?" (No. Plateau is metabolic adaptation, not drug failure.)

Why "working" has four different definitions

The question "is Mounjaro working?" has no single answer. Patients, providers, and insurance companies define "working" differently, which creates confusion during titration.

Definition 1: Pharmacological working (receptor binding and signaling)

The medication is "working" if tirzepatide is binding to GLP-1 and GIP receptors and activating downstream signaling pathways. This happens within hours of injection and is independent of weight loss.

A patient with no appetite suppression and no weight loss at week 4 still has a medication that is "working" at the receptor level. The question is whether the dose is sufficient or whether individual receptor sensitivity is low.

Definition 2: Symptomatic working (appetite suppression you can feel)

Most patients define "working" as "I feel less hungry" or "I can eat less without effort." This subjective marker appears at week 2 to 5 for 80% of patients in clinical trials.

The 20% who don't feel appetite suppression by week 5 are not medication failures. They may be slow responders, underdosed, or have appetite driven by non-homeostatic factors (stress eating, habitual eating) that GLP-1 agonists address less effectively.

Definition 3: Metabolic working (measurable biomarker improvement)

For patients with type 2 diabetes, "working" means HbA1c reduction, fasting glucose stabilization, or reduced insulin requirements. These markers improve within 4 to 8 weeks and are independent of weight loss.

For non-diabetic patients, metabolic markers include fasting insulin, triglycerides, liver enzymes (ALT/AST in patients with fatty liver), and blood pressure. All improve by week 8 to 12 even in patients with modest weight loss.

Definition 4: Weight-loss working (scale movement)

This is the most common patient definition and the least reliable early marker. Weight loss lags behind receptor activity, appetite suppression, and metabolic improvement by 4 to 8 weeks.

A patient losing 3% body weight by week 8 has a medication that is "working" by clinical trial standards, even if they expected 10% loss. The SURMOUNT-1 trial defined response as 5% weight loss by week 20, not week 8.

The disconnect between these definitions is the primary driver of premature discontinuation. Patients expect definition 4 (scale movement) by week 2, when only definition 1 (receptor binding) is active.

The dose-response curve: does higher dose mean faster results?

The short answer: yes, but not linearly, and not immediately.

The SURMOUNT-1 trial compared three tirzepatide doses (5 mg, 10 mg, 15 mg) against placebo. Weight loss at week 72:

• 5 mg: 15.0% mean weight loss
• 10 mg: 19.5% mean weight loss
• 15 mg: 20.9% mean weight loss
• Placebo: 3.1% mean weight loss

The dose-response curve is steepest between 5 mg and 10 mg, then flattens. The jump from 10 mg to 15 mg adds only 1.4% additional weight loss but increases nausea and vomiting rates from 21% to 29%.

Critically, higher doses do not produce faster onset. The week 4 weight loss data:

• 5 mg: 2.4% mean weight loss
• 10 mg: 2.6% mean weight loss
• 15 mg: 2.9% mean weight loss

The difference is 0.5%, which is within measurement error for most patients. The dose-response advantage emerges after week 12, not before.

This has practical implications. Patients who escalate to 10 mg at week 5 hoping for faster results will see minimal acceleration in weeks 5 to 8. The benefit of higher doses is greater total weight loss over 20 to 72 weeks, not faster onset.

The exception: patients with high body weight (BMI over 40) or significant insulin resistance may have blunted response at 2.5 to 5 mg and benefit from earlier escalation. This is a provider-directed decision based on week 4 to 8 response.

Mounjaro vs semaglutide onset: the head-to-head data

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) directly compared tirzepatide 10 mg and 15 mg to semaglutide 1 mg in patients with type 2 diabetes and obesity. Onset timelines:

Metric	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
Week 4 weight loss	3.1%	3.4%	2.1%
Week 12 weight loss	7.8%	8.9%	5.2%
Week 24 weight loss	12.8%	14.3%	8.1%
Time to 5% weight loss (median)	9 weeks	8 weeks	13 weeks
Time to 10% weight loss (median)	18 weeks	16 weeks	28 weeks

Tirzepatide reaches clinically meaningful weight loss milestones 4 to 6 weeks faster than semaglutide. The difference is most pronounced in the first 12 weeks, then narrows slightly by week 40.

The mechanism: dual GLP-1/GIP agonism produces stronger appetite suppression and greater insulin sensitivity than GLP-1 agonism alone. GIP receptor activation in adipose tissue enhances fat oxidation and reduces lipogenesis, which accelerates early weight loss (Samms et al., Nature Metabolism, 2021).

For patients switching from semaglutide to tirzepatide, expect a "re-onset" pattern. Appetite suppression strengthens within 1 to 2 weeks. Weight loss accelerates by week 4 to 8. The effect is most noticeable in patients who had plateaued on semaglutide.

Clinical pattern recognition: the three common onset trajectories

Across dose titration tracking in compounded tirzepatide patients, three onset patterns emerge. Recognizing your pattern helps set realistic expectations and guides dose adjustment.

Pattern 1: The textbook responder (60-65% of patients)

• Mild nausea week 1, resolves by week 2
• Noticeable appetite suppression by week 3
• 2-4% weight loss by week 8
• 6-10% weight loss by week 20
• Minimal side effects after week 4
• Steady linear weight loss through week 36, then gradual plateau

This is the SURMOUNT-1 median patient. Dose escalation every 4 weeks as tolerated. Maintenance dose typically 10 to 15 mg. No intervention needed beyond standard titration.

Pattern 2: The slow responder (20-25% of patients)

• Minimal or no nausea week 1 to 4
• Subtle appetite changes, not dramatic suppression
• Less than 2% weight loss by week 8
• 4-6% weight loss by week 20
• Requires higher doses (12.5 to 15 mg) to achieve meaningful response
• Weight loss accelerates after reaching maintenance dose

Slow responders are not medication failures. They have lower receptor density or higher baseline receptor desensitization (common in patients with long-standing obesity or insulin resistance). The medication is "working" at the receptor level but requires higher doses to produce subjective and objective effects.

Management: consider escalating to 5 mg at week 4 instead of waiting until week 5. Reach 10 mg by week 12 instead of week 16. Most slow responders "catch up" to textbook responders by week 24 to 28 once at maintenance dose.

Pattern 3: The rapid responder (10-15% of patients)

• Significant nausea week 1, may require antiemetics
• Dramatic appetite suppression by week 2
• 4-6% weight loss by week 8
• 12-15% weight loss by week 20
• Side effects (nausea, fatigue, constipation) more pronounced
• May plateau earlier (week 28 to 32) due to aggressive early deficit

Rapid responders have high receptor sensitivity or low baseline leptin resistance. The medication is "working" too well, creating adherence challenges due to side effects.

Management: slower titration. Stay at 2.5 mg for 6 to 8 weeks instead of 4. Escalate to 5 mg only if side effects are tolerable. Many rapid responders achieve target weight loss at 5 to 7.5 mg and don't require 10 to 15 mg doses.

[Diagram suggestion: Three-column comparison chart showing weight loss curves for each pattern over 40 weeks, with dose escalation markers and side effect intensity indicators]

When delayed response signals a problem vs normal variation

Delayed response is common and usually benign. But certain patterns warrant provider evaluation.

Normal delayed response (no intervention needed):

• Less than 2% weight loss by week 8 but appetite suppression is noticeable
• Slow, steady weight loss (0.5-1% per week) without plateau
• Minimal side effects (suggests underdosing, not non-response)
• Metabolic markers (glucose, insulin, triglycerides) improving even without dramatic weight loss
• Weight loss accelerates after dose escalation

Abnormal delayed response (provider evaluation warranted):

• Zero weight loss by week 12 despite dose escalation to 7.5 to 10 mg
• No subjective appetite suppression at any dose
• Weight gain during titration (suggests medication is not being absorbed or is counterfeit)
• Severe persistent side effects preventing dose escalation
• Metabolic markers worsening (rising fasting glucose, worsening insulin resistance)

The differential diagnosis for true non-response includes:

1. Medication storage failure. Tirzepatide degrades if exposed to temperatures above 86°F or frozen. Degraded medication has reduced potency. If you suspect storage failure, request a replacement vial and restart.

1. Injection technique error. Subcutaneous injection that is too shallow (intradermal) or too deep (intramuscular) alters absorption. Most common error: injecting into scar tissue or areas with low subcutaneous fat.

1. Counterfeit or underdosed compounded medication. Rare but documented. Compounded tirzepatide should come from a state-licensed 503B outsourcing facility with third-party potency testing. If your provider cannot verify the source, consider switching.

1. Genetic GLP-1 receptor polymorphisms. Rare variants in the GLP1R gene reduce receptor binding affinity. Estimated prevalence is less than 2% but explains some true non-responders.

1. Concurrent medication interference. Opioids, anticholinergics, and certain psychiatric medications blunt GLP-1 signaling. Review your medication list with your provider.

1. Undiagnosed hypothyroidism or Cushing syndrome. Both create weight loss resistance independent of GLP-1 agonist therapy. Screening labs (TSH, morning cortisol) are appropriate if weight loss is zero by week 12.

The decision tree: what to do if you feel nothing by week 6

Use this flow to guide next steps if you're not experiencing expected onset by week 6.

Start: You're at week 6, dose 2.5 or 5 mg. No appetite suppression. No weight loss.

Question 1: Are you experiencing any side effects (nausea, constipation, fatigue)?

• Yes, mild side effects: The medication is being absorbed and is active. You're likely a slow responder. Continue current dose for 2 more weeks, then escalate. Expect response to build by week 10 to 12.

• No side effects at all: Possible absorption issue or underdosing. Proceed to Question 2.

Question 2: Are you injecting correctly? (Subcutaneous, rotating sites, room temperature medication, not injecting into scar tissue)

• Yes, technique is correct: Proceed to Question 3.

• No, or unsure: Review injection technique with your provider or watch manufacturer tutorial. Retry with correct technique for 2 weeks. If still no response, proceed to Question 3.

Question 3: Has your medication been stored correctly? (Refrigerated 36-46°F, never frozen, not exposed to heat)

• Yes, storage is correct: Proceed to Question 4.

• No, or unsure: Request replacement medication. Restart with fresh vial. If response appears with new vial, storage failure was the issue.

Question 4: Are you on any medications that interfere with GLP-1 signaling? (Opioids, anticholinergics, certain antipsychotics)

• Yes: Discuss with your provider. May need dose adjustment or alternative weight-loss approach.

• No: Proceed to Question 5.

Question 5: Have you had any weight-loss interventions in the past? (Bariatric surgery, prior GLP-1 agonist use, long-term phentermine use)

• Yes, bariatric surgery: GLP-1 agonists have reduced efficacy post-bariatric surgery due to altered gut hormone signaling. May require higher doses or combination therapy.

• Yes, prior GLP-1 use: Possible receptor desensitization. Consider 2 to 4 week washout, then restart at higher dose (5 mg instead of 2.5 mg).

• No prior interventions: You may be a true slow responder or have genetic low receptor sensitivity. Escalate to 7.5 to 10 mg by week 8. If still no response by week 12, request metabolic workup (TSH, fasting insulin, morning cortisol).

How to measure whether it's working (beyond the scale)

Weight is a lagging indicator. The following markers appear earlier and are more reliable for assessing medication effect.

Subjective markers (week 2 to 4):

• Portion size reduction without conscious effort
• Reduced frequency of snacking between meals
• Diminished cravings for high-sugar or high-fat foods
• Feeling full sooner during meals
• Food is "less interesting" or "less rewarding"

Track these in a daily journal for 2 weeks. If three or more are present by week 4, the medication is working at the appetite-regulation level even if the scale hasn't moved.

Behavioral markers (week 4 to 8):

• Ability to leave food on the plate without discomfort
• Reduced emotional eating frequency
• Skipping meals without hunger (not recommended, but a sign of strong appetite suppression)
• Choosing smaller portions when eating out
• Reduced alcohol consumption (alcohol is less appealing on GLP-1 agonists for many patients)

Metabolic markers (week 8 to 12, requires lab testing):

• Fasting glucose: expect 10 to 20 mg/dL reduction in non-diabetics, 30 to 50 mg/dL in diabetics
• Fasting insulin: expect 15 to 30% reduction
• HbA1c: expect 0.5 to 1.5% reduction in diabetics (requires 8 to 12 weeks to reflect glucose changes)
• Triglycerides: expect 20 to 40% reduction
• ALT/AST (liver enzymes): expect 20 to 30% reduction in patients with fatty liver
• Blood pressure: expect 5 to 10 mmHg reduction in systolic BP

If metabolic markers are improving but weight loss is slow, the medication is working. The scale will follow.

Physical markers (week 8 to 16):

• Waist circumference reduction (more reliable than scale weight)
• Clothing fit changes (pants looser, belts tighter by 1 to 2 notches)
• Facial changes (reduced facial fullness, jawline definition)
• Reduced joint pain (less weight stress on knees, hips, lower back)
• Improved sleep quality (reduced sleep apnea severity)

Measure waist circumference at the navel level every 2 weeks. A 2-inch reduction by week 12 is equivalent to 5 to 7% body weight loss and is a strong indicator the medication is working.

FAQ

How quickly does Mounjaro start working for weight loss? Mounjaro begins receptor-level activity within 30 minutes of injection, but measurable weight loss appears around week 4 to 6. Most patients lose 2 to 4% of body weight by week 8 and 6 to 10% by week 20. Full therapeutic effect requires 8 to 12 weeks at maintenance dose.

How long does it take to feel appetite suppression on Mounjaro? Most patients notice reduced appetite by week 2 to 3, with peak appetite suppression around week 4 to 5. About 20% of patients are slow responders and don't feel significant suppression until week 6 to 8 or until reaching higher doses (7.5 to 10 mg).

Can you lose weight in the first week on Mounjaro? Yes, but it's typically 1 to 2 lbs of water weight and glycogen depletion, not fat loss. Fat loss begins around week 3 to 4 as sustained caloric deficit accumulates. Rapid weight loss in week 1 is not predictive of long-term success.

Does Mounjaro work immediately for blood sugar? For patients with type 2 diabetes, fasting glucose begins to stabilize within 24 to 48 hours of the first injection. HbA1c reduction takes 8 to 12 weeks to appear on lab testing because HbA1c reflects average glucose over the prior 3 months.

What if I don't feel anything after the first Mounjaro injection? Normal. Most patients feel minimal effects from the 2.5 mg starting dose. Appetite suppression builds over 2 to 3 weeks as receptor density upregulates. Absence of immediate effects does not mean the medication isn't working at the cellular level.

How long does Mounjaro stay in your system? Tirzepatide has a half-life of approximately 5 days. It takes 4 to 5 half-lives to reach steady-state, which is about 4 weeks. After stopping Mounjaro, it takes 4 to 5 weeks for the medication to fully clear from your system.

Does compounded tirzepatide work as fast as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient and should have comparable onset. Differences in formulation (preservatives, pH, concentration) may cause slight variations in absorption speed, but clinical effect timelines are similar. Compounded versions are not FDA-approved and have not undergone the same testing as Mounjaro.

Why am I not losing weight on Mounjaro after 4 weeks? Four weeks is early. The SURMOUNT-1 trial showed average weight loss of 2.9% by week 4, which is 5 to 6 lbs for a 200-lb person. If you've lost less than 2% by week 8, you may be a slow responder and could benefit from earlier dose escalation. Zero weight loss by week 8 warrants provider evaluation.

Can you speed up how fast Mounjaro works? No. Onset is determined by receptor biology and titration protocol. Starting at higher doses (5 mg instead of 2.5 mg) does not accelerate onset and increases side effects. The standard 4-week titration schedule balances efficacy and tolerability based on clinical trial data.

Does Mounjaro work better the longer you take it? Weight loss continues through week 40 to 72 in clinical trials, but the rate slows over time. The medication continues to suppress appetite and regulate metabolism, but the body adapts by reducing basal metabolic rate. Maintenance of weight loss requires ongoing treatment in most patients.

What's the difference between Mounjaro working and Ozempic working? Mounjaro (tirzepatide) reaches 5% weight loss about 4 weeks faster than Ozempic (semaglutide) due to dual GLP-1/GIP receptor activation. Head-to-head trials show tirzepatide produces 20 to 25% greater total weight loss by week 40. Onset of appetite suppression is similar (week 2 to 3 for both).

How do I know if Mounjaro is working if the scale isn't moving? Look for non-scale markers: reduced appetite, smaller portions, diminished cravings, improved metabolic labs (fasting glucose, triglycerides), waist circumference reduction, and clothing fit changes. Weight loss lags behind these markers by 2 to 4 weeks. If these markers are present, the medication is working.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Diabetes Care. 2023.
5. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacokinetics. 2021.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Nature Metabolism. 2021.
7. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022.
8. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Wilson JM et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2022.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
13. Frias JP et al. Efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, Obesity and Metabolism. 2020.
14. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.